SIEN Sientra

Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SANTA BARBARA, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that on August 29, 2022, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 49 new employees.

The new employees were granted restricted stock units representing a total of 1,182,029 shares of common stock. The restricted stock units will vest in time-based installments beginning on the grant date. In each case, the vesting of shares is contingent upon the recipient’s continued service with the Company through each vesting date.

The grants were made as an inducement that was a material component of each person’s compensation and subsequent acceptance of employment with the Company and were granted as employment inducement awards pursuant to NASDAQ Listing Rule 5635(c)(4) approved by the Compensation Committee.

About Sientra

Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons (*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at .

(*) Data on file

Investor Relations Contact 

Aman R. Patel, CFA



Source: Sientra, Inc.

 



EN
06/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sientra

 PRESS RELEASE

Sientra Announces Completion and Winning Bidders of its Section 363 Sa...

Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra’s breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra’s BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (“Sientra” or the “Company”) announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC (“Tiger”) has been declared t...

 PRESS RELEASE

Sientra to Pursue Strategic Sale of its Business Through Voluntary Cha...

Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process Company secures $22.5 million of new money in debtor-in-possession financing from existing lenders to support ongoing operations during the sale process IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on F...

 PRESS RELEASE

Sientra Reports Third Quarter Financial and Operational Results

Sientra Reports Third Quarter Financial and Operational Results IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, a...

 PRESS RELEASE

Sientra to Present at the Stifel 2023 Healthcare Conference

Sientra to Present at the Stifel 2023 Healthcare Conference IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its participation at the Stifel 2023 Healthcare Conference. As part of the conference, the company’s management team will participate in a live fireside chat on Wednesday, November 15, 2023 at 8:00am EST / 5:00am PST. An on-demand webcast of the presentation will be accessible under “News & Ev...

 PRESS RELEASE

Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Res...

Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch